Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics

Landmark double-blind, placebo-controlled clinical pharmacology trial characterizing ayahuasca's subjective, cardiovascular, and pharmacokinetic effects in 18 experienced volunteers. Established dose-dependent increases in subjective effects, moderate cardiovascular stimulation, and pharmacokinetic profiles of DMT and harmala alkaloids.